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Abstract
Background: The Study of Healthcare Personnel with Influenza and other Respiratory Viruses in Israel (SHIRI)
prospectively follows a cohort of healthcare personnel (HCP) in two hospitals in Israel. SHIRI will describe the
frequency of influenza virus infections among HCP, identify predictors of vaccine acceptance, examine how
repeated influenza vaccination may modify immunogenicity, and evaluate influenza vaccine effectiveness in
preventing influenza illness and missed work.
Methods: Cohort enrollment began in October, 2016; a second year of the study and a second wave of cohort
enrollment began in June 2017. The study will run for at least 3 years and will follow approximately 2000 HCP
(who are both employees and members of Clalit Health Services [CHS]) with routine direct patient contact.
Eligible HCP are recruited using a stratified sampling strategy. After informed consent, participants complete a
brief enrollment survey with questions about occupational responsibilities and knowledge, attitudes, and practices about
influenza vaccines. Blood samples are collected at enrollment and at the end of influenza season; HCP who choose to be
vaccinated contribute additional blood one month after vaccination. During the influenza season, participants receive
twice-weekly short message service (SMS) messages asking them if they have acute respiratory illness or febrile illness
(ARFI) symptoms. Ill participants receive follow-up SMS messages to confirm illness symptoms and duration and are asked
to self-collect a nasal swab. Information on socio-economic characteristics, current and past medical conditions, medical
care utilization and vaccination history is extracted from the CHS database. Information about missed work due to illness
is obtained by self-report and from employee records. Respiratory specimens from self-collected nasal swabs are tested
for influenza A and B viruses, respiratory syncytial virus, human metapneumovirus, and coronaviruses using validated
multiplex quantitative real-time reverse transcription polymerase chain reaction assays. The hemagglutination inhibition
assay will be used to detect the presence of neutralizing influenza antibodies in serum.
Discussion: SHIRI will expand our knowledge of the burden of respiratory viral infections among HCP and the
effectiveness of current and repeated annual influenza vaccination in preventing influenza illness, medical
utilization, and missed workdays among HCP who are in direct contact with patients.
Trial registration: NCT03331991. Registered on November 6, 2017.
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Background
Healthcare personnel (HCP) are believed to be at increased
risk of respiratory viral infections, with one in five estimated
to be infected with seasonal influenza each year [1]. These
estimates vary widely, however, depending on the extent of
active surveillance and the use of serologic vs. molecular
diagnostics. Respiratory infections are of particular concern
among HCP because of the close contact of HCP with pa-
tients [2], and the risk of HCP transmitting respiratory vi-
ruses to others [3]. Although recent research suggests that
certain subgroups of HCP, such as those who perform aero-
sol-generating procedures, may be at heightened risk of in-
fection with influenza and other respiratory pathogens [4],
incidence of infections among HCP is not well character-
ized across different occupations and responsibilities. Fur-
thermore, although HCP often work while ill [5–7], the
extent to which infected HCP transmit respiratory patho-
gens to patients is not clear [8]. Further research is needed
on the frequency and types of interactions HCP have with
patients when they have symptomatic, atypical, or
asymptomatic [1, 9] influenza virus infections.
Vaccination of HCP against influenza is an important
component of infection control in healthcare settings [10],
but persistently low rates of vaccine uptake among HCP in
most countries remains an international concern [10–12].
Numerous studies on the knowledge, attitudes, and prac-
tices (KAP) associated with influenza vaccine acceptance
and rejection have been conducted among HCP in
high-income countries in North America and Europe
[13–16]. However, much less is known about the bar-
riers to vaccine acceptance among HCP in countries in
the Middle East [12]. In Israel, a high-income country,
less than half (49%) of HCP received influenza vaccine
for the 2015–2016 influenza season; vaccine coverage
was somewhat higher among hospital-based physicians
(53%) than nurses (46%) [17]. More information is
needed on the occupational, socio-demographic, and
KAP factors that may explain variations in influenza
vaccine acceptance in Israel, including how the per-
sonal KAP of HCP may impact on their promotion of
influenza vaccination among their patients.
Although recent reviews confirm that the seasonal
influenza vaccine is moderately effective in reducing
the risk of influenza illness among adults [18], mul-
tiple gaps in knowledge remain about the preventive
value of the vaccine among HCP [1]. To date, there
has been only one randomized controlled trial of influenza
vaccine efficacy among HCP, and this study measured
serologic outcomes only [19]. Given that vaccinated
individuals are less likely to seroconvert after an influ-
enza virus infection and so can appear as not having
been infected [20, 21], the use of serologic outcomes
likely biases (and specifically, inflates) vaccine efficacy
estimates.
Gaps are especially evident in our understanding of
the value of influenza vaccine for reducing secondary ad-
verse outcomes, including nosocomial infections among
patients [22, 23] and missed work due to illness [24, 25].
Evidence is also needed to validate the potential of the
vaccine in reducing the severity and duration of disease
and diminish infectiousness among those who have break-
through infections despite being vaccinated [24, 26]. Be-
cause HCP often receive influenza vaccine during multiple
years, studies of HCP also provide an opportunity to exam-
ine how prior vaccinations may modify immunogenicity
and vaccine effectiveness, and may provide answers to
questions regarding the extent of residual protection and/
or negative vaccine interference across seasons [27–29].
Here we provide an overview of the design and methods
of a prospective study of influenza vaccine effectiveness in
HCP named “Study of Healthcare Personnel with Influ-
enza and other Respiratory Viruses in Israel” (SHIRI). The
SHIRI cohort will follow approximately 600 HCP, all of
whom have direct patient contact, during at least three in-
fluenza seasons, and an additional 1400 HCP during at
least two influenza seasons.
Our study has four primary objectives: (1) to describe
the frequency of respiratory, atypical (e.g., febrile only),
and asymptomatic influenza virus infection among HCP;
(2) to identify predictors of vaccine acceptance (and
hesitancy) among HCP; (3) to examine how repeated in-
fluenza vaccination may modify immunogenicity; and (4)
to evaluate influenza vaccine effectiveness in preventing
influenza illness, associated missed work, and working
while ill. Table 1 lists the knowledge gaps we identified
within each of these aims and the study features intended
to address these gaps.
The findings of this study will contribute to our know-
ledge about the burden of influenza and the vaccine effect-
iveness among HCP, and thus may influence a vaccination
policy change in Israel and internationally.
Methods/design
Study design
This prospective cohort study of influenza vaccine ef-
fectiveness in HCP is funded by the United States Cen-
ters for Disease Control and Prevention (US CDC). A
steering committee, consisting of principal investigators
from the two hospitals, Clalit Health Services (CHS), the
Israeli Center for Disease Control, Abt Associates, and the
US CDC was established and charged with making critical
decisions related to the study. Additional investigators
from the University of Michigan School of Public Health
and the Ben Gurion University School of Public Health
will advise on laboratory methods and qualitative methods
related to the study. Study activities are described in
Fig. 1.
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Setting
The study is being conducted among HCP at two hospitals
in Israel: (1) Soroka University Medical Center (located in
Beer Sheva, a city in southern Israel), and (2) Beilinson
Hospital (located in Petah Tivka, a city in central Israel)
(Table 2). Both hospitals are managed and primarily staffed
Table 1 Study Goals and Features Intended to Address Specific Knowledge Gaps
Knowledge Gap Study Feature
1. Description of the frequency of influenza virus infection among healthcare personnel, including those manifesting as acute respiratory illness,
atypical illness, or asymptomatic infection
Studies of influenza illness among HCP using laboratory-confirmed
outcomes are scarce.
Identification of symptomatic influenza virus infections with mqRT-PCR
assay.
Typical surveillance strategies have focused on acute respiratory
illness using highly specific case definitions which overlook non-
respiratory and non-febrile manifestations of influenza disease.
Usage of a broad case definition: “illness with cough, runny nose, body
aches, or feverishness in the past seven days.”
Few studies have used both molecular and serologic diagnostics
to assess the total burden of influenza virus infection among HCP.
In addition to mqRT-PCR, 4-fold increases in HI from pre- to post-season
will also be used to identify possible influenza virus infection among
unvaccinated HCP.
It is unclear how differences in sex, age, occupation, and underlying
health may contribute to the frequency of influenza illness among
HCP.
Usage of random stratified sampling to enroll a mixture of HCP by sex,
age, and occupation. Assess underlying health status by self-report and
medical record extraction.
Further research is needed on whether specific HCP roles and
responsibilities increase the risk of infection with influenza and
other respiratory pathogens.
Comparison of the frequency of ARFI (and infection with influenza and
other respiratory viruses) by number of hours of direct patient care and
by performance of aerosol-generating procedures (such as suction of
fluids and tracheal intubation).
More information is needed on the impact of influenza illness
on HCP’s absence from work due to illness and working while ill.
Assessment of the duration of illness, missed, and rescheduled work due
to illness, hours worked during illness, and ability to do usual activities.
2. Identification of predictors of vaccine acceptance (and hesitancy)
Most studies of HCP have focused on influenza vaccine uptake
in specific seasons and less on behavior over multiple years.
Description of how the frequency of influenza vaccination during the
five years prior to enrollment and during the two to three years of
participation in the cohort varies by sex, age, occupation, and
socio-economic status.
Most studies of KAP associated
with influenza vaccination among HCP have been conducted
in the United States or Western European countries.
This study is conducted in Israel, and will examine KAP topics including
association between frequency of vaccination and perceived susceptibility
to influenza, perceived benefits and risks of influenza vaccination, readiness
to be vaccinated, and anticipated worry and regret about influenza
vaccination decisions.
3. Examination of how repeated influenza vaccination may modify immunogenicity
Few studies have assessed the effects of repeated influenza
vaccination across multiple seasons on immunogenicity.
Examination of how HI differs depending on the receipt of influenza
vaccines up to ten years prior to the study for consistent health plans
members.
Further research is needed on the mechanisms through which
prior vaccination affects immunogenicity.
Examination of whether any link between repeated vaccination and HI
can be explained by HCP’s “antibody landscape”.
Further research is needed on whether repeated prior vaccination
impacts cell mediated immune response to influenza vaccines.
In a subset of participants who provide peripheral blood mononuclear
cells before and after vaccination, examination of whether repeated
prior vaccination is associated with suppression of B-cell and T-cell
immunogenicity.
4. Evaluation of influenza vaccine effectiveness in preventing influenza illness and associated missed work and working while ill
Prior study of IVE among HCP used serologic outcomes, which
are likely biased among vaccinees.
Estimate the effectiveness of the influenza vaccine in preventing
mqRT-PCR confirmed influenza illness among HCP.
It is unclear whether influenza vaccines may reduce missed work due
to influenza illness or reduce time spent working while ill (i.e.,
presenteeism) with influenza.
Examine the hours of missed work and presenteeism between the dates
of onset and resolution of influenza illness; apply these observations to
estimate potential IVE in averting missed work or presenteeism.
More information is needed on the extent to which prior
vaccination may offer residual protection and/or interfere with
IVE in subsequent seasons.
Examination of IVE associated with combinations of current season
vaccination and frequent vs. infrequent prior vaccinations.
Further research is needed on whether the influenza vaccination may
modify influenza disease severity and duration among those who
become infected despite vaccination.
Among HCP with influenza illness, examination of whether symptom
severity and illness duration are lower among vaccinated vs.
unvaccinated HCP.
Abbreviations: HCP healthcare personnel, mqRT-PCR multiplex quantitative real-time reverse transcription polymerase chain reaction, HI hemagglutination
inhibition, ARFI acute respiratory illness or febrile illness, KAP knowledge, attitudes, and practices, IVE influenza vaccine effectiveness
Hirsch et al. BMC Infectious Diseases          (2018) 18:550 Page 3 of 14
by CHS, the largest insurer and integrated care provider in
Israel with over 4.4 million members in 2017, which consti-
tute over 50% of the population.
Participants
Eligibility criteria
Eligible participants include HCP employed at a partici-
pating hospital who meet the following criteria: at least
18 years old; work full-time (≥30 h per week); and have
routine direct hands-on or face-to-face contact with
patients (within one meter) as part of a typical work
shift. These eligibility criteria are similar to previous
studies of HCP with direct patient contact [24, 30]. Par-
ticipation is offered to physicians, nurses, respiratory
therapists, physical therapists, unit clerks, radiograph
technicians, medical assistants, transporters, and other
Fig. 1 Steps in Recruitment, Enrollment, and Follow-up
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HCP who have direct contact with patients. All partici-
pants must also be members of CHS and have had con-
tinuous membership in CHS for at least 1 year prior to
enrollment (in order to access medical and vaccination
records). HCP are invited to join the study whether or
not they intend to be vaccinated. HCP are excluded if
they received the current season’s flu vaccine more than
48 h before enrollment. If enrollment goals are not met,
some enrollment restrictions can be eliminated (e.g., re-
quiring prior year membership in the Clalit health plan,
working, ≥30 h per week, or plans to stay at the facility
for at least 2 years) and differences in outcomes by these
characteristics can be examined analytically.
Eligibility is determined by reviewing CHS’s electronic
medical record (EMR), which contains information on
all of the eligibility criteria listed above except for the
number of working hours, which is determined in the
recruitment phone call. EMR data is extracted at the
Clalit Research Institute, the research arm of CHS.
Screening information is logged in the Research Elec-
tronic Data Capture (REDCap), a common database (de-
scribed below).
Recruitment
In order to recruit HCP with diverse socio-demographic
characteristics, occupational responsibilities, and influ-
enza vaccination histories, eligible HCP were invited to
participate using a stratified sampling strategy that tar-
geted eligible participants in groups (strata) categorized by
sex, age, occupation, and previous year influenza vaccin-
ation status. This systematic approach was intended to
minimize convenience sampling, which can introduce
both known and unknown biases. Each group includes in-
dividuals with unique characteristics known to potentially
affect influenza vaccine immunogenicity and effectiveness.
At CHS, a list of eligible HCP at each facility was gen-
erated and categorized into groups based on age (18–34,
35–49, ≥50 years old), sex, occupational categories (1-
Physicians; 2 - Nurses, medical therapists, and profes-
sional technicians; and 3 - Medical assistants and support
staff ), and prior season influenza vaccination status (yes
vs. no). Thus, prior to each year of the study, the sample is
drawn from 36 unique strata (2 sexes * 3 age groups * 3
occupation groups * 2 prior season vaccination status
groups). This stratified sampling strategy will be applied
to potential new participants each year.
At each hospital, goals are set for the minimum and
maximum number of enrollees per strata; then, recruit-
ment is implemented in three waves. During the first
wave of recruitment, HCP from the 36 strata are invited
at random to participate in the study. Next, in Wave 2,
we identify study strata where additional recruitment is
needed and expand direct invitations to additional HCP
who have not yet been invited to join the study. In strata
where all HCP have been contacted but recruitment
goals have not been met, we will recruit similar HCP,
prioritizing HCP who are similar in previous vaccination
status, followed by age, sex, and lastly by profession. Fi-
nally, in Wave 3, we accept volunteers to meet the total
sample goals for each facility. All potential enrollees will
be recorded in a recruitment log in order to track invita-
tions, acceptance, and refusal and reasons for refusal.
Timeline of enrollment
A total cohort of 2000 HCP will be enrolled over a
three-year period. Enrollment periods are targeted prior
to influenza seasons. During Year 1 of the study, which
targeted the 2016/2017 influenza season, enrollment could
not begin until October 6, 2016 due to funding and insti-
tutional approval delays. Recruitment continued until the
start of the influenza season (December 4, 2016) for a total
of 8 weeks. This recruitment period included a month of
frequent Israeli national holidays (October 2016), during
which enrollment was challenging because many HCP
were on vacation. In Year 1 of the study, 596 HCP were
enrolled, and will contribute to Years 1, 2 and 3 of this
3-year cohort study. Enrollment in Year 2 began in June
2017. New enrollees in Year 2 will contribute to Years 2
and 3 of the study.
Active surveillance
During the influenza season, participants receive twice-
weekly short message service (SMS) messages asking them
to confirm whether they have acute illness symptoms,
Table 2 Study Sites
Name of study site Location Number of employees Number Of beds Number of eligible
participants, 2016c
Number of eligible
participants, 2017d
Soroka University Medical Center Beer Sheva, Israel 4300b 1074a 2436 2853
Beilinson Hospital Petah Tikva, Israel 5500b 850b 1988 2260
aData as of 2016; Data were extracted from Israeli Ministry of Health reports
bData of 2017; Data were extracted from employee records from the CHS EHR and Israeli Ministry of Health reports
cRecruitment in 2016 began in October, when nationwide vaccination was already in progress. HCP who had already been vaccinated in the current season were
not eligible for the study
dExcludes participants enrolled in 2016
Number of beds data was obtained from Israeli Ministry of Health reports
Abbreviations: CHS Clalit Health Services, EMR electronic medical record, HCP healthcare personnel
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defined as one or more of the following symptoms within
the past 7 days: cough, runny nose, body aches, or feverish-
ness. In addition to these SMS messages, participants are
asked to contact the study staff immediately when they ex-
perience symptoms of acute illness. If a participant reports
an acute illness, he or she is asked follow-up questions
about specific symptoms and date of onset. Participants are
first contacted by SMS message. If they do not respond,
they are contacted by telephone. If participants do not re-
spond to phone calls, an attempt is made to contact them
in-person. Ill participants receive follow-up SMS messages
about whether the illness has resolved. Once an illness
resolution is reported by a participant, he or she is sent five
follow-up questions by SMS message about illness presen-
tation, duration, and impact on work attendance. These
surveillance activities are described in Fig. 2.
The start and end of active surveillance is determined
by the study investigators and steering committee based on
historical patterns for seasonal influenza circulation and
available clinical and surveillance indicators of laboratory-
confirmed influenza virus circulation in Israel. In the first
year of the study, active surveillance started on December
4, 2016 and continued through March 23, 2017.
Data collection
We collect data for all participants from multiple sources.
Key variables and their sources in the years prior to the study
and during each study year are summarized in Table 3.
Electronic medical records
Information on socio-demographic characteristics, current
medical conditions, medical history, medical care utilization,
and influenza vaccination history are extracted from the
CHS EMR at enrollment and at the end of each study year.
For all participants, chronic medical conditions are identified
using a combination of the International Classification of
Diseases, Ninth Revision (ICD-9) codes from inpatient and
outpatient records, International Classification of Primary
Care Coding (ICPC), physician-entered free text diagnoses
from outpatient medical records, and electronic chronic dis-
ease registries maintained by the Clalit Research Institute
(details in Additional file 1: Annex 1 and Annex 2).
Routine influenza vaccine administration for CHS HCP
members who receive the vaccine is recorded in the health
fund’s EMR. Because the vaccine is offered free of charge
for members in CHS hospitals and clinics, nearly all of
those who are vaccinated do so in such settings. Partici-
pants are considered vaccinated for a specific season if
they received influenza vaccine from September 1 through
March 31 of the relevant influenza season. To date, influ-
enza vaccine has not been offered in Israel prior to Sep-
tember 1. We document prior vaccine history, according
to EMR records, from the the 2006–2007 season, 10 years
prior to the first year of our study.
In addition, we document medical visits for ARFI dur-
ing weeks of active surveillance in every study year. We
also document medically attended ARFI in the 10 years
prior to enrollment, distinguishing between medical visits
that occurred during the influenza season and those that
occurred outside of the influenza season. Medically
attended ARFI episodes during active surveillance and
for years prior to enrollment are captured through
evaluation of outpatient visits, emergency room visits, and
hospital admissions. Criteria used for medically attended
ARFI are described in Additional file 1: Annex 3.
Outpatient visits, emergency room visits, medications
dispensed at CHS pharmacies, and hospital admissions
are regularly updated in the CHS EMR, making it pos-
sible to document medical visits nearly in real-time by
recording ICD-9 codes and free text entered by physi-
cians. We also access the EMR to document influenza
antiviral medications and antibiotics dispensed during
acute illnesses.
Self-reported data
At enrollment and at the beginning of each subsequent
season, all participants complete a brief survey with
questions about socio-demographic characteristics that
are not available in the EMR, occupational responsibil-
ities, health status, and KAP regarding seasonal influ-
enza vaccination.
At the end of each influenza season, participants are
asked to complete another brief survey that includes
questions about their overall health and to describe pre-
viously unreported illnesses (‘End-of-season survey’).
Surveys are designed to be self-administered electronic-
ally through the Internet using the REDCap system.
Work absenteeism
During active surveillance, we document days of missed
work associated with respiratory illnesses. Missed work-
days are identified by self-report (as part of acute illness
and illness follow-up SMS messages) and by periodic re-
views of human resource department employee absentee
records. Illness days are identified as all days between
self-reported illness onset and illness resolution dates
(from SMS surveillance messages or by direct phone
screening). Thus, missed work due to illness includes
days that participants directly reported missing due to
illness and days of absence (according to employee re-
cords) between the illness onset and resolution dates.
Laboratory methods
Nasal specimens
When participating HCP report being ill with a respiratory
illness during the influenza season, they are instructed to
self-collect a nasal swab using a self-swabbing kit [31] that
includes illustrated instructions, a nasal mid-turbinate
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swab, and a tube with room temperature transport
medium. Respiratory specimens are placed in viral
transport medium and delivered to the respective hos-
pitals from HCP’s residences by a courier service or
are hand-carried by participants to study staff at their
respective hospitals. If participants prefer not to collect
the nasal swab themselves, study staff are able to collect it
for them.
Molecular diagnostics
Specimens from Beilinson Hospital are stored at 4 °C and
delivered by courier to the Clinical Virology Laboratory
(CVL) at Soroka University Medical Center twice a week,
where they are immediately aliquoted and frozen at − 80 °C.
Specimens from participating Soroka University Medical
Center HCP are brought to the laboratory daily, where they
are aliquoted and frozen.
Fig. 2 Active Surveillance SMS Messaging Flow
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Table 3 Key Variables and Sources of Information for Participants
Self-reported Electronic Medical
Records
Time Period
Enrollment
survey
EOS
survey
EMR Employee
Records
From year(s)
prior to the study
Data from years
enrolled in study
Demographic
Sex ✓
Date of birth ✓
Marital status ✓ ✓ ✓
Country of birth ✓ ✓
Immigration date ✓ ✓
Ethnicity by country of birth of individual, the parents, or
grandparents
✓ ✓
Socio-economic status by clinic address ✓ ✓ ✓
Supplementary insurance status ✓ ✓
Dates enrolled as CHS member ✓ ✓
Level of education ✓ ✓
Household composition (number of rooms;
number of family members in the house)
✓ ✓
Occupation and work responsibilities ✓ ✓ ✓
Family income ✓ ✓
Health Status and Risk Behaviors
Health status and health behaviors ✓ ✓ ✓
Smoking status, history ✓ ✓
Pack years ✓ ✓
Height ✓ ✓
Weight ✓ ✓
Body mass index ✓ ✓
Medication use for chronic conditions and
immunosuppressants
✓ ✓
Attitudes
Perceptions of illness, vaccines, missing work ✓ ✓
Recollection of influenza vaccination
(for vaccinated HCP)
✓ ✓
Reasons for not receiving the influenza
vaccine (for unvaccinated HCP)
✓ ✓
Job satisfaction ✓ ✓
Influenza Vaccination Documentation
Vaccine administration date ✓ ✓ ✓
Vaccine type ✓ ✓ ✓
Vaccine manufacturer & lot ✓ ✓ ✓
Employee Records of Illness Absences ✓ ✓
Acute Respiratory Illness
Number of inpatient admissions associated
with acute illness
✓ ✓ ✓
Chronic Medical Conditions and Pregnancy
Number of ambulatory or inpatient medical
encounters associated with chronic medical
condition
✓ ✓ ✓
Chronic medical conditions ✓ ✓
Pregnancy ✓ ✓
Abbreviations: EOS end of season, EMR electronic medical record, CHS Clalit health plan, HCP healthcare personnel
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After one freeze-thaw cycle, specimens are tested for
influenza A viruses [A(H1N1)pdm09 and A(H3N2)],
influenza B viruses, respiratory syncytial virus (RSV),
human metapneumovirus, and coronaviruses (NL63,
229E, OC43, HKU1) using validated multiplex quantita-
tive real-time reverse transcription polymerase chain re-
action (mqRT-PCR) assays [32], with protocols, primers,
probes, and reagents supplied by Hy-labs (Israel) and
Integrated DNA Technologies (USA). The CVL, in
collaboration with the University of Michigan (Ann
Arbor, Michigan, US), has completed the World Health
Organization and US CDC influenza proficiency panels.
Quality Control for Molecular Diagnostics (Glasgow,
Scotland, UK) proficiency panels were also completed
for influenza, RSV, human metapneumovirus (hMPV)
and coronaviruses.
Some specimens will have molecular characterization
with genetic sequencing and other assays to detect gen-
etic markers to determine viral subclades and antiviral
resistance at a reference laboratory approved by the
study steering committee. Remaining aliquots of all study
specimens may be sent to a US CDC-designated facility
(also approved by the study steering committee) for add-
itional virus characterization, banking, and storage. No
specimens will contain personal identifiers.
Blood Specimens At enrollment, prior to each influenza
season, 10 mL specimens of whole blood are collected
from all participants. In addition, 5 mL specimens of
whole blood are collected at the end of season 1 and the
start and end of subsequent seasons. Participants who
received the influenza vaccine during the study period
will be asked to provide an additional sample of 5 mL of
whole blood approximately 28 days (within a range of
21–42 days) after vaccination. Sera are extracted from
whole blood and stored frozen until testing.
Participants who consent to providing additional blood
at enrollment, as an optional part of the study, provide
an additional 10 mL heparinized whole blood at enroll-
ment and the end of season for extraction of peripheral
blood mononuclear cells (PBMC). In addition, we collect
10 mL of heparinized whole blood approximately 7 days
after vaccination from participants who agree to this op-
tional part of the study. All PBMC samples are centri-
fuged, undergo cell count, diluted to 1-5 × 106 cells/ml
and gradually frozen to − 80 °C, and placed in liquid ni-
trogen within 24 h. PBMC samples will be used for
cell-mediated immunity assays.
Hemagglutination inhibition assay
The hemagglutination inhibition (HI) assay will be used
to detect the presence of influenza antibodies in serum.
HI to inactivated influenza vaccine components and in-
fluenza circulating strains will be performed at a
reference laboratory using standard methods [33] as de-
scribed previously [28, 34] (See Additional file 1: Annex 4).
Egg-grown viruses will be supplied by the US CDC’s Inter-
national Reagent Resource. Preparation of serum samples
will include (a) treatment with a receptor-destroying en-
zyme to remove nonspecific inhibitors, and (b) removal of
nonspecific agglutinins by serum adsorption with packed
red blood cells (RBC). Standard 0.5% turkey RBC will be
prepared for influenza A (H1N1)pdm09 antigens and
ether-treated B influenza antigens. Given indications
that neuraminidase of circulating antigenic clusters of
influenza A(H3N2) viruses (since 2014) have acquired
the ability to bind to RBC, modified HI assays will be
conducted for influenza A(H3N2) antigens using guinea
pig red blood cells in the presence of the antiviral oselta-
mivir carboxylate, which inhibits influenza neuraminidase.
Serum will be diluted 2-fold starting from 1:10. The HI
titer will be the reciprocal of the serum dilution in the last
well with complete HI. The geometric mean titer from du-
plicate results will be reported; HI < 10 will be considered
5 for the purposes of statistical analyses.
Additional immunological assays
Additional serologic testing may occur, including neur-
aminidase inhibition assay testing, antigen microarray
testing [35] and other approaches. Neuraminidase-specific
antibodies have been shown to play a role in protection
against influenza infection [36, 37]. However, many ques-
tions remain about the role of neuraminidase in vaccine
effectiveness [38].
Attitudes toward morbidity due to influenza and other
respiratory illnesses
As a sub-study within this project, approximately 15–25
in-depth open-ended qualitative interviews are con-
ducted each year with participants who recently had a
wintertime respiratory illness and agree to participate in
this sub-study.
Participants are contacted by phone approximately 1
week after confirmation of respiratory illness resolution
and asked to participate in an interview. Interviews
cover topics including illness experience, including
symptoms, duration, perceived severity, and disruption
to their daily activities and responsibilities, perceptions
of how the illness impacted work responsibilities, per-
ceptions of how the illness impacted life outside of work,
and reasons for choosing to receive or not receive the
influenza vaccine this season (see Additional file 1:
Annex 5). Interviews will be recorded by audio recorder
and later transcribed. After transcription, the data are
translated from Hebrew to English and qualitatively
analyzed using NVivo Software (QSR International,
Melbourne, Australia) to identify themed code-words
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that may point to common patterns of comments
across the interviews.
Data management
REDCap
Data collection and site-level management are con-
ducted using REDCap, a browser-based metadata-driven
software system (Vanderbilt University, Nashville, TN,
USA) [39]. Most study instruments, including the re-
cruitment log, online surveys, and laboratory results,
allow for real-time data entry directly into REDCap. Sur-
veys are designed to be self-administered electronically
through the Internet using home computers, personal
mobile telephones, or on computers or tablets provided at
the workplace by study staff. In addition, study staff enter
participants’ responses directly into the REDCap database
for interviews administered by telephone. Routine quality
assurance monitoring is conducted locally by the project
manager and centrally by the data coordinator (Abt Asso-
ciates). Missing or unclear information is corrected
through follow-up contact with participants.
TextIt
TextIt (TextIt, Kigali, Rwanda) is an online platform that
uses logic flows to send tailored SMS messages to partic-
ipants. Custom decision trees were developed in order
to trigger exchanges with participants during active sur-
veillance (described above). Specifically, TextIt docu-
ments answers to weekly illness inquiries, dates of illness
onset and resolution, ratings of symptoms, and missed
work. Study staff perform bi-weekly exports of TextIt
data and import the data into an Excel macro-enabled
workbook in order to track participant responses and ill-
ness events over time (see Additional file 1: Annex 6 for
more details about TextIt).
Statistical considerations
Cohort size
The required number of participants depends on mul-
tiple factors, including expected influenza attack rate,
vaccination coverage, and anticipated study attrition. We
estimated that with 2340 participants contributing 5
months at-risk for influenza infection per season, 40%
vaccine coverage, and 10% influenza illness attack rate,
we would be powered to estimate a true vaccine effect-
iveness of 50% with confidence intervals that do not
overlap with zero.
Sample size for incidence calculations
The full cohort provides the sample needs for estimating
the frequency (or incidence within the study sample) of
influenza illness. Given the larger sample demands for
the vaccine effectiveness objectives, we expect to have
ample statistical power for most objectives that involve
estimating incidence or frequencies.
Sample size for immune response to vaccine and infection
objectives
To assess the immune response to the vaccine, we plan
to collect serum from the cohort members prior to vac-
cine availability, after vaccination, and at the end of each
season. Our study design mirrors approaches used in pre-
vious studies that assessed the HI antibody titers among
HCP analyzed sera from subgroups of 300–800 partici-
pants who provided sera at the same three time points
[28]. See Additional file 1: Annex 7 for more details.
Data analysis of VE
Rates of acute illness associated with mqRT-PCR con-
firmed influenza virus infection (influenza illness) will be
calculated as the number of influenza illnesses divided
by person-time measured in weeks of active surveillance.
Regression models will be used to estimate influenza
vaccine effectiveness (1 – rate of influenza illness among
vaccinated HCP/rate among unvaccinated HCP * 100)
with 95% confidence intervals. Adjusted models of influ-
enza vaccine effectiveness will include study year, calen-
dar time (i.e., weeks between illness onset and week of
peak of influenza season), and a propensity for vaccin-
ation score calculated using multivariable logistic regres-
sion [40]. Other potential confounders, including study
site, will be examined and included in the adjusted
model if they change IVE point estimates by > 5%.
Data analysis of immunogenicity
Since distributions of HI titer data are typically highly
left-skewed, all statistical analyses will be conducted
using log base-2 transformed titer data; results are then
back-transformed to the original scale for ease of interpret-
ation [28, 41]. Pre- and post-vaccine draws are assumed to
be correlated within each person, thus repeated measures
linear mixed models will be fitted to estimate geometric
mean titers (GMT) and geometric mean ratios (GMR).
Compound symmetric covariance error structures will be
assumed for repeated measures within individuals. GMT
will be calculated by back-transforming the least squares
mean estimates of logged titer data. GMR will be calculated
by back-transforming the difference of least squares means
of post-vaccination and pre-vaccination logged titer esti-
mates. GMR will be interpreted as the geometric mean fold
ratio of post-vaccination titer to pre-vaccination titer.
Multivariate estimates adjusted a priori for age and sex.
Linear, quadractic, and cubic terms for age will be exam-
ined to consider possible nonlinear associations with age.
Other covariates (e.g., education, household size, working
in a hospital setting) may also be adjusted within multivari-
able models if they were associated with the number of
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prior vaccinations and either preseason GMT or post-vac-
cination GMR among vaccines.
Ethical considerations
The study protocol and procedures have been reviewed
and approved by the Helsinki committees (institutional
review board) at both of the study sites, and by Abt As-
sociates (the coordinating institution on which US CDC
relies). In addition, extraction of data from the CHS
EMR was approved by the Data Use Committee of the
Clalit Research Institute.
All participants complete written informed consent in
Hebrew. Small gifts (such as a gift card) are given to par-
ticipants at study milestones like completion of enroll-
ment, blood draws, and completion of end-of-season
survey. Influenza test results are given to those partici-
pants who ask to receive them. Given the research na-
ture of the laboratory methods and time delays in batch
testing, mqRT-PCR findings are not available to inform
clinical decisions.
Discussion
We described the recruitment, enrollment, active sur-
veillance, data collection, laboratory methods, and data
management procedures for the SHIRI cohort – a US
CDC-sponsored prospective study, overseen by CHS, of
approximately 2300 HCP at two hospitals in Israel. In
this study, we will describe the frequency of influenza
virus infections among HCP in Israel. Using a broad case
definition of respiratory illness, we aim to identify a wide
range of ARFI in order to assess more accurately the
burden of respiratory illness among HCP. Due to CHS’s
extensive EMR, we will have the ability to look at HCP
influenza vaccination records up to 10 years prior to
study enrollment in order to better understand how HI
antibody titers differ depending on the number and specific
combinations of prior influenza vaccinations. We will also
be able to evaluate influenza vaccine effectiveness in pre-
venting medically attended and non-medically attended in-
fluenza illness and associated missed work days.
The findings from the SHIRI cohort will increase our
understanding of the burden of acute respiratory ill-
nesses, and influenza virus illness specifically, among
HCP in Israel. The unique design of the study, which
includes comprehensive medical and vaccination data,
active surveillance using a broad case definition, and
both molecular and serologic diagnostics, will provide
important data on influenza vaccine immunogenicity
and effectiveness among HCP. The combination of in-
sights about influenza burden and vaccine effectiveness
may potentially inform influenza vaccine policy for
HCP in Israel and internationally.
Strengths
Our study benefits from the fact that all enrolled HCP
are members of CHS, and therefore extensive information
is recorded in the EMR, which provides real-time data
about ambulatory visits, hospitalizations, and medication
use. In addition, the EMR provides reliable historic data
about the participants, such as prior vaccination informa-
tion, socio-economic variables, and data about health sta-
tus and health behaviors. In our study, even if an ARFI is
not reported through the SMS surveillance system, daily
monitoring of the EMR for medical visits and medications
will allow us to identify illnesses and contact participants
directly in order to collect respiratory specimens and
complete the illness survey. Combining our study with
EMR data and data from the two hospitals’ human re-
sources departments will also allow us to reliably map the
impact of illness on missed work and to evaluate days
worked when ill (presenteeism).
In addition, the broad case definition of an ARFI
promises to be more sensitive for influenza illness than
case definitions used in previous HCP research [24] and
should allow us to characterize a continuum of mild to
moderately severe illnesses. Another strength is that the
two study sites (Soroka University Medical Center and
Beilinson Hospital) are among the largest hospitals in
Israel, and the populations they serve and the HCP they
employ vary in socio-demographic and economic char-
acteristics. Soroka University Medical Center, the only
general hospital in the Negev region in southern Israel,
serves two main local populations: Jews, who mostly live
in urban settings, and Bedouin Arabs, who live in a
range of settlement types, from cities to unrecognized
rural villages that lack electricity and running water [42,
43]. Beilinson Hospital, located in central Israel, serves a
mostly urban population of a relatively higher
socio-economic status compared to Soroka University
Medical Center. Conducting our study in these two dif-
ferent settings may allow us to identify
socio-demographic differences in KAP, vaccine uptake,
and influenza illness attack rates. The use of mixed
methods, including laboratory, clinical and epidemio-
logical quantitative data, and in-depth qualitative inter-
views, creates a comprehensive approach, which is
particularly important when trying to understand issues of
influenza vaccine compliance and hesitancy. Finally, the
study cohort includes several unique sub-studies.
Limitations
Our study has at least four limitations. First, our ability
to generalize vaccine effectiveness findings from the
study years to the potential preventive value of an influ-
enza vaccine program may be limited. The effectiveness
of the vaccine depends in part on the types of viruses
circulating and the antigenic and genetic match between
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vaccine components and circulating strains in a given
year. The precision of the estimates will also depend on
the number of influenza cases.
Second, we will be cautious in interpreting self-reported
information, given potential biases in recall and self-pres-
entation. While some of the information collected
through active surveillance can be verified with admin-
istrative data, other information, such as symptoms for
non-medically attended illnesses, cannot be verified by
another data source.
Third, although the random stratified sampling design
intentionally includes HCP with a mixture of character-
istics and work responsibilities, there are relatively few
HCP in some of the strata. For example, few male med-
ical assistants and support personnel are employed at
the two hospitals, and therefore it is unlikely that we will
be able to enroll large numbers from this category. This
may limit our ability to examine the association between
the frequency of influenza illness and specific combina-
tions of age, sex, and occupation.
Fourth, during the third wave of recruitment we accept
volunteers, regardless of age, profession, or vaccine status,
which can present a sampling bias. However, characteris-
tics of these volunteer participants will be compared with
those of participants recruited during the first two waves
in order to evaluate potential differences between the
groups.
Additional file
Additional file 1: Description of additional terms and methods used in
the Study of Healthcare Personnel with Influenza and other Respiratory
Viruses in Israel. (DOCX 77 kb)
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